Live Breaking News & Updates on Institutional trading of vertex pharmaceuticals

Stay updated with breaking news from Institutional trading of vertex pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given Average Rating of "Hold" by Brokerages

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given Average Rating of "Hold" by Brokerages
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Colorado , United-states , William-blair , Sanfordc-bernstein , Amit-sachdev , Stuarta-arbuckle , Institutional-trading-of-vertex-pharmaceuticals , Analyst-recommendations-for-vertex-pharmaceuticals , Maxim-group , News-ratings-for-vertex-pharmaceuticals-daily , Vertex-pharmaceuticals-trading , Macquarie-group-ltd

Vertex Pharmaceuticals (NASDAQ:VRTX) Downgraded by StockNews.com

StockNews.com cut shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday morning. A number of other equities analysts have also recently weighed in on the stock. Truist Financial upped their price objective on shares of Vertex Pharmaceuticals from $456.00 […] ....

Sherbrooke , Quebec , Canada , Zurcher-kantonalbank-zurich-cantonalbank , Ourania-tatsis , News-ratings-for-vertex-pharmaceuticals-daily , Vertex-pharmaceuticals-price-performance , Jpmorgan-chase-co , Vertex-pharmaceuticals , Wolfe-research , Morgan-stanley , Sherbrooke-park-advisers

Cantor Fitzgerald Reiterates "Overweight" Rating for Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “overweight” rating reissued by research analysts at Cantor Fitzgerald in a research report issued on Tuesday, Benzinga reports. They presently have a $440.00 price objective on the pharmaceutical company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 5.44% from the company’s current price. […] ....

Canada , William-blair , Robertw-baird , Kristen-ambrose , Stifel-nicolaus , Cantor-fitzgerald , Vertex-pharmaceuticals-incorporated , Insider-activity-at-vertex-pharmaceuticals , Sageview-advisory-group , Morgan-stanley , News-ratings-for-vertex-pharmaceuticals-daily , Childress-capital-advisors

Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $438.00

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective hoisted by equities research analysts at JPMorgan Chase & Co. from $390.00 to $438.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage currently has an “overweight” rating on the pharmaceutical company’s stock. JPMorgan Chase & Co.‘s price […] ....

Brucei-sachs , Robertw-baird , News-ratings-for-vertex-pharmaceuticals-daily , Lindbrook-capital , Vertex-pharmaceuticals , Sumitomo-mitsui-ds-asset-management-company-ltd , Vertex-pharmaceuticals-trading-down , Jpmorgan-chase-co , Analyst-recommendations-for-vertex-pharmaceuticals , Vertex-pharmaceuticals-incorporated , Vertex-pharmaceuticals-company-profile

Vertex Pharmaceuticals (NASDAQ:VRTX) Cut to "Sell" at Canaccord Genuity Group

Canaccord Genuity Group cut shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning, MarketBeat.com reports. The brokerage currently has $379.00 target price on the pharmaceutical company’s stock, up from their prior target price of $332.00. VRTX has been […] ....

Stifel-nicolaus , Brucei-sachs , Carmen-bozic , Zurcher-kantonalbank-zurich-cantonalbank , Insider-transactions-at-vertex-pharmaceuticals , Analyst-recommendations-for-vertex-pharmaceuticals , Bogart-wealth , Vertex-pharmaceuticals-trading , Securities-exchange-commission , Vertex-pharmaceuticals , Institutional-trading-of-vertex-pharmaceuticals , Canaccord-genuity-group